| Banff 07 classification of renal allograft pathology: updates and future directions K Solez, RB Colvin, LC Racusen, M Haas, B Sis, M Mengel, PF Halloran, ... American journal of transplantation 8 (4), 753-760, 2008 | 2303 | 2008 |
| Banff’05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (’CAN’) K Solez, RB Colvin, LC Racusen, B Sis, PF Halloran, PE Birk, ... American Journal of Transplantation 7 (3), 518-526, 2007 | 1393 | 2007 |
| Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients H Vlaminck, B Maes, G Evers, G Verbeke, E Lerut, B Van Damme, ... American Journal of transplantation 4 (9), 1509-1513, 2004 | 318 | 2004 |
| Mapping of pelvic lymph node metastases in prostate cancer S Joniau, L Van den Bergh, E Lerut, CM Deroose, K Haustermans, ... European urology 63 (3), 450-458, 2013 | 265 | 2013 |
| CYP3A5 and CYP3A4 but not MDR1 Single‐nucleotide Polymorphisms Determine Long‐term Tacrolimus Disposition and Drug‐related Nephrotoxicity in Renal … DRJ Kuypers, H de Jonge, M Naesens, E Lerut, K Verbeke, ... Clinical pharmacology & therapeutics 82 (6), 711-725, 2007 | 265 | 2007 |
| Intrarenal resistive index after renal transplantation M Naesens, L Heylen, E Lerut, K Claes, L De Wever, F Claus, R Oyen, ... New England Journal of Medicine 369 (19), 1797-1806, 2013 | 231 | 2013 |
| Adjuvant low‐dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients DRJ Kuypers, AK Vandooren, E Lerut, P Evenepoel, K Claes, R Snoeck, ... American Journal of Transplantation 5 (8), 1997-2004, 2005 | 212 | 2005 |
| Multiparametric MRI for prostate cancer localization in correlation to whole‐mount histopathology S Isebaert, L Van den Bergh, K Haustermans, S Joniau, E Lerut, ... Journal of magnetic resonance imaging 37 (6), 1392-1401, 2013 | 207 | 2013 |
| Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate … T Budiharto, S Joniau, E Lerut, L Van den Bergh, F Mottaghy, ... European urology 60 (1), 125-130, 2011 | 199 | 2011 |
| Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and chronic kidney failure M Živná, H Hůlková, M Matignon, K Hodaňová, P Vylet'al, M Kalbáčová, ... The American Journal of Human Genetics 85 (2), 204-213, 2009 | 185 | 2009 |
| Expression of complement components differs between kidney allografts from living and deceased donors M Naesens, L Li, L Ying, P Sansanwal, TK Sigdel, SC Hsieh, N Kambham, ... Journal of the American Society of Nephrology 20 (8), 1839-1851, 2009 | 174 | 2009 |
| Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts M Naesens, E Lerut, H de Jonge, B Van Damme, Y Vanrenterghem, ... Journal of the American Society of Nephrology 20 (11), 2468-2480, 2009 | 171 | 2009 |
| High‐level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB T Van de Sande, T Roskams, E Lerut, S Joniau, H Van Poppel, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2005 | 165 | 2005 |
| The histology of kidney transplant failure: a long-term follow-up study M Naesens, DRJ Kuypers, K De Vusser, P Evenepoel, K Claes, ... Transplantation 98 (4), 427-435, 2014 | 161 | 2014 |
| Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients DRJ Kuypers, M Naesens, H de Jonge, E Lerut, K Verbeke, ... Therapeutic drug monitoring 32 (4), 394-404, 2010 | 152 | 2010 |
| Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 … B Kneitz, M Krebs, C Kalogirou, M Schubert, S Joniau, H van Poppel, ... Cancer research 74 (9), 2591-2603, 2014 | 145 | 2014 |
| Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases B Beuselinck, P Wolter, A Karadimou, R Elaidi, H Dumez, A Rogiers, ... British Journal of Cancer 107 (10), 1665-1671, 2012 | 138 | 2012 |
| High intrapatient variability of tacrolimus concentrations predicts accelerated progression of chronic histologic lesions in renal recipients T Vanhove, T Vermeulen, P Annaert, E Lerut, DRJ Kuypers American Journal of Transplantation 16 (10), 2954-2963, 2016 | 137 | 2016 |
| Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: clinical presentation and implications for outcome A Senev, M Coemans, E Lerut, V Van Sandt, L Daniëls, D Kuypers, ... American Journal of Transplantation 19 (3), 763-780, 2019 | 124 | 2019 |
| Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial P Schöffski, A Wozniak, B Escudier, P Rutkowski, A Anthoney, S Bauer, ... European Journal of Cancer 87, 147-163, 2017 | 124 | 2017 |
